← Back to Home

First-in-human trial of triple-target CAR-T: 16-patient study shows efficacy signals, with a median of 7 days from blood collection to infusion

Designed to recognize three cancer cell markers simultaneously and incorporate OX40 costimulation, this early-stage cell therapy produced remissions in some patients with lymphoma. But the small phase 1 trial is not yet sufficient to establish superiority over existing treatments.

By SURL BioNews

For patients with relapsed or treatment-refractory B-cell blood cancers, cell therapy faces two challenges: whether it can continue to recognize cancer cells and whether it can reach patients in time. A first-in-human phase 1 trial by a team at The Ohio State University in the United States combined triple-target recognition with rapid on-site manufacturing. Preliminary efficacy was observed in 16 treated participants, providing a basis for further research.

The study has been published in *Blood Cancer Discovery*, and news released by the university in October was also covered by ecancer. The study's CAR-T cells target CD19, CD20 and CD22 simultaneously and incorporate an OX40 costimulatory domain into the receptor to help transmit T-cell activation signals. The multi-target design aims to reduce the chance that tumors evade recognition by losing a single marker; however, this trial cannot yet establish that it has reduced the risk of relapse.

The trial enrolled 18 people, of whom 16 received a cell infusion. According to reporting on the same study, participants had a median age of 64 years and had received a median of three types of prior treatment, reflecting a heavily pretreated patient population. The study included different B-cell malignancies, so differences between disease types must also be considered when interpreting the overall results.

Manufacturing speed was another focus. CAR-T therapy requires collecting a patient's T cells, modifying them in a laboratory and then infusing them back into the patient. The paper's abstract reported a median time of 7 days from blood collection to infusion. News coverage separately described a six-day rapid preparation process; the two cannot be treated directly as the same time metric. For this study, the clearer finding is that rapid on-site manufacturing and infusion were feasible. This does not yet support conclusions about cost or availability.

Regarding efficacy, the paper's abstract reported an overall response rate of 50% and a complete response rate of 83% in the lymphoma subgroup. These figures have different denominators, and the latter cannot be applied to everyone who received treatment. The reporting noted remissions in mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. The study's one-year overall survival rate was 61%, but this is not equivalent to a one-year relapse-free rate.

Safety data showed no severe cytokine release syndrome and no neurotoxicity in the trial. This is a signal supporting further research, but it cannot be interpreted as an absence of other side effects or as ruling out rare risks. With only 16 people treated, the study is also too small to determine whether this design is safer than existing CAR-T therapies.

The study also found that features of T-cell exhaustion at collection were associated with subsequent disease progression, suggesting that the state of the starting cells may affect treatment performance. This association is not yet a validated criterion for patient selection. Larger patient cohorts and longer follow-up are needed to clarify which diseases are most likely to benefit, how long remissions can last, and how much the triple-target and OX40 designs each contribute.

References

  1. Newswise
  2. Blood Cancer Discovery via PubMed
  3. ecancer